Down Syndrome News and Research

Latest Down Syndrome News and Research

Catatonia may cause regression in Down syndrome patients

Down syndrome, the most common chromosomal disorder in America, can be complicated by significant deterioration in movement, speech and functioning in some adolescents and young adults. Physicians previously attributed this regression to depression or early-onset Alzheimer's, and it has not responded to treatments.

13 May 2015

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics Inc. today announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company.

6 May 2015

Vanderbilt biologists explore how electrochemical connections form at molecular and cellular level

Every time you make a memory, somewhere in your brain a tiny filament reaches out from one neuron and forms an electrochemical connection to a neighboring neuron.

27 Apr 2015

Natera, LifeLabs sign new agreement for non-invasive prenatal testing in Canada

Natera, Inc., a global leader in non-invasive genetic testing, and LifeLabs Medical Laboratory Services today announced a new agreement that gives LifeLabs the rights to perform non-invasive prenatal testing (NIPT) in Canada using Natera technology.

From Natera 25 Apr 2015

Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Thanks to the generosity of a philanthropy dedicated to children's issues, renowned Down syndrome researcher Alberto Costa, MD, PhD, has taken yet another step toward making Northeast Ohio the nation's leader in exploring potential treatments of the genetic condition that affects 400,000 people in the U.S.

23 Apr 2015

Findings of Ariosa's non-invasive prenatal testing study published online in NEJM

Results from the largest clinical trial to date, comparing non-invasive prenatal testing (NIPT) using the Harmony Prenatal Test with conventional first trimester combined screening (FTS) in a general pregnancy population have been published online in The New England Journal of Medicine.

6 Apr 2015

New prenatal test introduced for detecting Down’s Syndrome

A new prenatal test for Down’s Syndrome may be more effective at diagnosing the condition than the standard screening that is currently used, suggests a study published in the New England Journal of Medicine.

2 Apr 2015

Transition announces positive results from ELND005 AME and renal clearance studies

Transition Therapeutics Inc. today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME") study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration for the approval of most drugs in development.

26 Mar 2015

Position statement on promise, challenges of non-invasive prenatal testing

Two of the world's largest professional societies of human geneticists have issued a joint position statement on the promise and challenges of non-invasive prenatal testing (NIPT), a new procedure to test blood drawn from pregnant mothers for Down syndrome and other chromosomal disorders in the fetus.

26 Mar 2015

Physicians develop new quality measures for treatment of childhood obstructive sleep apnea

A work group of physicians from leading academic medical centers across the country, including NYU Langone Medical Center, has developed new quality measures for the detection and treatment of childhood obstructive sleep apnea (OSA), a potentially morbid, life-altering condition that affects hundreds of thousands of children and adolescents nationwide.

16 Mar 2015

Transition completes enrolment of patients in ELND005 Phase 2 study for treatment of AD patients

Transition Therapeutics Inc. announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited completed enrolment of the Phase 2 clinical study evaluating neuropsychiatric drug candidate ELND005 as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer's disease ("AD").

2 Mar 2015

Einstein researchers find possible clue to why older mothers have babies born with Down syndrome

Researchers at Albert Einstein College of Medicine of Yeshiva University have found a possible clue to why older mothers face a higher risk for having babies born with conditions such as Down syndrome that are characterized by abnormal chromosome numbers.

19 Feb 2015

New computer-simulated prescribing strategies for glasses may help Down syndrome patients see better

New computer-simulated prescribing strategies for glasses may improve the vision of individuals with Down syndrome, thanks to a team of University of Houston College of Optometry researchers who received a $1.67 million grant from the National Eye Institute.

12 Feb 2015

Transition Therapeutics commences underwritten public offering of common shares

Transition Therapeutics Inc. announced today that it has commenced an underwritten public offering of its common shares.

12 Feb 2015

Cell free DNA analysis less effective than sequential screening in finding fetal chromosomal abnormalities

In a study to be presented on Feb. 5 in an oral plenary session at 8 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in San Diego, researchers will report that cell free DNA analysis is less effective than sequential screening as primary testing for fetal chromosomal abnormalities.

5 Feb 2015

Alzheimer's brains commonly have many neurons with more DNA and genomic copies of APP gene

Scientists at The Scripps Research Institute have found diverse genomic changes in single neurons from the brains of Alzheimer's patients, pointing to an unexpected factor that may underpin the most common form of the disease.

5 Feb 2015

Cell-free fetal DNA testing more effective in detecting Down syndrome

Cell-free fetal DNA testing, which measures the relative amount of free fetal DNA in a pregnant woman's blood, is a new screening test that indicates the risk of Down syndrome (trisomy 21), Edward syndrome (trisomy 18), and Patau syndrome (trisomy 13).

3 Feb 2015

Maternal age and successful egg freezing with PGS: an interview with Dr. Santiago Munné

The leading cause of of pregnancy loss or infertility is chromosomal abnormality or imbalance, where extra genetic material is present or some is missing - what’s called aneuploidy. This imbalance leads to the inability to produce viable embryos or pregnancy.

2 Dec 2014

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Transition Therapeutics Inc. ("Transition" or the "Company") today announced findings from a Phase 2 study of neuropsychiatric drug candidate, ELND005, as an adjunctive maintenance treatment for bipolar disorder type I patients (BPD).

4 Nov 2014

Researchers to develop new tests to evaluate cognitive growth in people with intellectual disability

Leading researchers, funded through a new, five-year, $3.2 million grant from the National Institutes of Health, are collaborating to develop and evaluate tests designed to measure and track changes in the cognitive functioning of people who typically are difficult to assess accurately: those with an intellectual disability, formerly termed mental retardation.

3 Nov 2014

Down Syndrome News and Research

Latest Down Syndrome News and Research

Catatonia may cause regression in Down syndrome patients

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Vanderbilt biologists explore how electrochemical connections form at molecular and cellular level

Natera, LifeLabs sign new agreement for non-invasive prenatal testing in Canada

Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Findings of Ariosa's non-invasive prenatal testing study published online in NEJM

New prenatal test introduced for detecting Down’s Syndrome

Transition announces positive results from ELND005 AME and renal clearance studies

Position statement on promise, challenges of non-invasive prenatal testing

Physicians develop new quality measures for treatment of childhood obstructive sleep apnea

Transition completes enrolment of patients in ELND005 Phase 2 study for treatment of AD patients

Einstein researchers find possible clue to why older mothers have babies born with Down syndrome

New computer-simulated prescribing strategies for glasses may help Down syndrome patients see better

Transition Therapeutics commences underwritten public offering of common shares

Cell free DNA analysis less effective than sequential screening in finding fetal chromosomal abnormalities

Alzheimer's brains commonly have many neurons with more DNA and genomic copies of APP gene

Cell-free fetal DNA testing more effective in detecting Down syndrome

Maternal age and successful egg freezing with PGS: an interview with Dr. Santiago Munné

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Researchers to develop new tests to evaluate cognitive growth in people with intellectual disability

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Down Syndrome News and Research

Latest Down Syndrome News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in